Toews Corporation’s AbbVie ABBV Stock Holding History

Toews Corporation’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,100	Closed	-$760K	–	12
2023 Q3	$760K	Buy	+5,100	New	+$749K	0.46%	78
2023 Q1	–	Sell	-4,800	Closed	-$776K	–	20
2022 Q4	$776K	Sell	4,800 -3,700	-44%	-$567K	0.38%	63
2022 Q3	$1.14M	Buy	8,500 +500	+6%	+$71.7K	0.84%	14
2022 Q2	$1.23M	Buy	8,000 +5,500	+220%	+$840K	0.82%	27
2022 Q1	$405K	Buy	+2,500	New	+$363K	0.07%	68
2021 Q4	–	Sell	-3,800	Closed	-$410K	–	22
2021 Q3	$410K	Buy	+3,800	New	+$434K	0.05%	48
2021 Q2	–	Sell	-8,900	Closed	-$963K	–	16
2021 Q1	$963K	Buy	+8,900	New	+$952K	0.08%	24
2020 Q4	–	Sell	-11,100	Closed	-$972K	–	22
2020 Q3	$972K	Buy	+11,100	New	+$1.05M	0.29%	95

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Toews Corporation's ABBV Position: Q4 2023 in Review

Toews Corporation sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 5,100 shares — an estimated $760K sold.

Toews Corporation first reported a position in ABBV in Q3 2020 and held it in 8 quarters. The position peaked at $1.23M in Q2 2022. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

Toews Corporation reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
Toews Corporation sold 5,100 AbbVie shares in Q4 2023, an estimated $760K.
Toews Corporation first reported a position in AbbVie in Q3 2020 and held it in 8 quarters.
Toews Corporation's AbbVie position peaked at $1.23M in Q2 2022.
3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Toews Corporation's 13F filing for Q4 2023, filed 17 Jan 2024.